Table 1.
Effect of ruboxistaurin on laboratory measures and endothelial biomarkers
| Healthy
|
Diabetes
|
|||
|---|---|---|---|---|
| Placebo | Ruboxistaurin | Placebo | Ruboxistaurin | |
| Laboratory measures | ||||
| MAP (mm Hg) | 85.3 ± 15.5 | 90.0 ± 17.3 | 98.1 ± 11.2a | 98.7 ± 11.7 |
| Total cholesterol (mg/dl) | 176 ± 27 | 179 ± 27 | 178 ± 33 | 190 ± 39 |
| LDL cholesterol (mg/dl) | 105 ± 23 | 105 ± 23 | 100 ± 39 | 114 ± 39 |
| HDL cholesterol (mg/dl) | 51 ± 16 | 51 ± 16 | 44 ± 13 | 54 ± 39 |
| Triglycerides (mg/dl) | 107 ± 71 | 107 ± 98 | 176 ± 89b | 198 ± 89b |
| Glucose (mg/dl) | 92.6 ± 10.9 | 94.7 ± 10.4 | 185.2 ± 70.2b | 174.6 ± 61.2b |
| ALT (U/liter) | 20 ± 7.5 | 23.6 ± 7.6 | 26.1 ± 16.3 | 26.8 ± 17.8 |
| Endothelial biomarkers | ||||
| hsCRP (mg/liter) | 0.67 (0.46–1.8) | 1.05 (0.52–2.44) | 2.2 (1.25–10.24)a | 1.54 (0.81–3.67) |
| PAI-1 (ng/ml) | 2.03 (1.15–4.10) | 3.41 (1.97–5.79) | 5.62 (3.63–8.09) | 3.23 (1.53–6.92) |
| sVCAM (ng/ml) | 398.4 (292.2–432.9) | 430.3 (360.0–538.3) | 396.0 (314.6–536.6) | 427.4 (309.2–562.8) |
| vWF | 80.4 (56.8–98.1) | 60.9 (20.9–87.3) | 85.3 (49.5–111.8) | 108.0 (51.3–115.1) |
| NT (nm) | 12.2 (1.4–54.0) | 3.2 (0.2–16.2) | 2.1 (0.2–17.8) | 3.5 (0.2–17.8) |
ALT, Alanine aminotransferase; HDL, high-density lipoprotein.
a
P < 0.05 for comparison with control placebo.
b
P = 0.001 for comparison with same treatment period in control subjects.